HRP20210608T1 - Postupci i pripravci za induciranje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije - Google Patents
Postupci i pripravci za induciranje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije Download PDFInfo
- Publication number
- HRP20210608T1 HRP20210608T1 HRP20210608TT HRP20210608T HRP20210608T1 HR P20210608 T1 HRP20210608 T1 HR P20210608T1 HR P20210608T T HRP20210608T T HR P20210608TT HR P20210608 T HRP20210608 T HR P20210608T HR P20210608 T1 HRP20210608 T1 HR P20210608T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- preparation
- effective amount
- additional
- use according
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title claims 23
- 239000000203 mixture Substances 0.000 title claims 13
- 238000000034 method Methods 0.000 title claims 6
- 230000001939 inductive effect Effects 0.000 title claims 5
- 230000001681 protective effect Effects 0.000 title claims 3
- 230000036039 immunity Effects 0.000 title 1
- 230000009385 viral infection Effects 0.000 title 1
- 239000013598 vector Substances 0.000 claims 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 230000003053 immunization Effects 0.000 claims 11
- 238000002649 immunization Methods 0.000 claims 11
- 239000002671 adjuvant Substances 0.000 claims 10
- 229960005486 vaccine Drugs 0.000 claims 10
- 230000000890 antigenic effect Effects 0.000 claims 8
- 239000003937 drug carrier Substances 0.000 claims 8
- 230000028993 immune response Effects 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 101710121417 Envelope glycoprotein Proteins 0.000 claims 6
- 102100021696 Syncytin-1 Human genes 0.000 claims 6
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical group O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 5
- 239000012752 auxiliary agent Substances 0.000 claims 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 3
- 229930182490 saponin Natural products 0.000 claims 3
- 150000007949 saponins Chemical class 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Claims (15)
1. Kombinacija cjepiva, naznačena time, da je za uporabu u postupku induciranja imunosnog odgovora protiv virusa humane imunodeficijencije (HIV) kod pojedinca, pri čemu navedena kombinacija sadrži:
(i) prvi pripravak koji sadrži imunogenetski učinkovitu količinu jednog ili više adenovirusnih 26 vektora (rAd26) koji kodiraju HIV antigene polipeptide s aminokiselinskim sljedovima od SEQ ID NO: 1, SEQ ID NO: 3 i SEQ ID NO: 4, i farmaceutski prihvatljiv nosač;
(ii) drugi pripravak koji sadrži imunogenetski učinkovitu količinu izoliranog HIV glikoproteina ovojnice s aminokiselinskim slijedom od SEQ ID NO: 5 ili SEQ ID NO: 6, pomoćno sredstvo, i farmaceutski prihvatljiv nosač; i
(iii) imunogenetski učinkovitu količinu jednog ili više dodatnih rAd26 vektora koji kodiraju HIV antigene polipeptide s aminokiselinskim sljedovima od SEQ ID NO: 1, SEQ ID NO: 3 i SEQ ID NO: 4,
pri čemu se prvi pripravak daje za primarnu imunizaciju i drugi pripravak se daje za dodatnu pojačanu imunizaciju, i imunogenetski učinkovita količina dodatnih rAd26 vektora, nalazi se u drugom pripravku ili u trećem pripravku koji se daje zajedno s drugim pripravkom za dodatnu pojačanu imunizaciju.
2. Kombinacija cjepiva za uporabu prema patentnom zahtjevu 1, naznačena time, da se imunogenetski učinkovita količina jednog ili više dodatnih rAd26 vektora nalazi u trećem pripravku.
3. Kombinacija cjepiva za uporabu prema patentnom zahtjevu 1 ili 2, naznačena time, da se kod pomoćnog sredstva radi o aluminijevom fosfatu ili pomoćnom sredstvu na bazi saponina.
4. Kombinacija cjepiva za uporabu prema patentnom zahtjevu 3, naznačena time, da pomoćno sredstvo jest aluminijev fosfat.
5. Kombinacija cjepiva za uporabu prema bilo kojem od patentnih zahtjeva 1 do 4, naznačena time, da izolirani HIV glikoprotein ovojnice posjeduje aminokiselinski slijed od SEQ ID NO: 5.
6. Kombinacija cjepiva za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačena time, da spomenuti imunosni odgovor jest zaštitni imunosni odgovor protiv HIV infekcije.
7. Komplet, naznačen time, da obuhvaća kombinaciju cjepiva za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5.
8. Kombinacija cjepiva, naznačena time, da je za uporabu u induciranju imunosnog odgovora protiv virusa humane imunodeficijencije (HIV) kod pojedinca, pri čemu navedena kombinacija cjepiva sadrži:
(i) prvi pripravak koji sadrži imunogenetski učinkovitu količinu jednog ili više adenovirusnih 26 vektora (rAd26) koji kodiraju HIV antigene polipeptide s aminokiselinskim sljedovima od SEQ ID NO: 1, SEQ ID NO: 3 i SEQ ID NO: 4, i farmaceutski prihvatljiv nosač;
(ii) drugi pripravak koji sadrži imunogenetski učinkovitu količinu izoliranog HIV glikoproteina ovojnice s aminokiselinskim slijedom od SEQ ID NO: 5, farmaceutski prihvatljiv nosač, i pomoćno sredstvo, gdje je pomoćno sredstvo aluminijev fosfat ili pomoćno sredstvo na bazi saponina; i
(iii) treći pripravak koji sadrži imunogenetski učinkovitu količinu jednog ili više dodatnih rAd26 vektora koji kodiraju HIV antigene polipeptide s aminokiselinskim sljedovima od SEQ ID NO: 1, SEQ ID NO: 3 i SEQ ID NO: 4,
pri čemu se prvi pripravak daje za primarnu imunizaciju, a drugi pripravak se daje zajedno s trećim pripravkom za dodatnu pojačanu imunizaciju.
9. Kombinacija cjepiva za uporabu prema patentnom zahtjevu 8, naznačena time, da pomoćno sredstvo jest aluminijev fosfat.
10. Prvi pripravak, naznačen time, da sadrži imunogenetski učinkovitu količinu jednog ili više adenovirusnih 26 vektora (rAd26) koji kodiraju HIV antigene polipeptide s aminokiselinskim sljedovima od SEQ ID NO: 1, SEQ ID NO: 3 i SEQ ID NO: 4, i farmaceutski prihvatljiv nosač, za uporabu s drugim pripravkom koji sadrži imunogenetski učinkovitu količinu izoliranog HIV glikoproteina ovojnice s aminokiselinskim slijedom od SEQ ID NO: 5 ili SEQ ID NO: 6, pomoćno sredstvo, i farmaceutski prihvatljiv nosač, i imunogenetski učinkovitu količinu jednog ili više dodatnih rAd26 vektora koji kodiraju HIV antigene polipeptide s aminokiselinskim sljedovima od SEQ ID NO: 1, SEQ ID NO: 3 i SEQ ID NO: 4,
u postupku induciranja imunosnog odgovora protiv virusa humane imunodeficijencije (HIV) kod pojedinca,
gdje navedeni postupak obuhvaća davanje navedenog prvog pripravka za primarnu imunizaciju, davanje navedenog drugog pripravka za dodatnu pojačanu imunizaciju, i davanje imunogenetski učinkovite količine dodatnih rAd26 vektora, pri čemu se navedena imunogenetski učinkovita količina dodatnih rAd26 vektora nalazi u drugom pripravku ili u trećem pripravku koji se daje zajedno s drugim pripravkom za dodatnu pojačanu imunizaciju.
11. Drugi pripravak, naznačen time, da sadrži imunogenetski učinkovitu količinu izoliranog HIV glikoproteina ovojnice s aminokiselinskim slijedom od SEQ ID NO: 5 ili SEQ ID NO: 6, pomoćno sredstvo, i farmaceutski prihvatljiv nosač, za uporabu s prvim pripravkom koji sadrži imunogenetski učinkovitu količinu jednog ili više adenovirusnih 26 vektora (rAd26) koji kodiraju HIV antigene polipeptide s aminokiselinskim sljedovima od SEQ ID NO: 1, SEQ ID NO: 3 i SEQ ID NO: 4, i farmaceutski prihvatljiv nosač, i imunogenetski učinkovitu količinu jednog ili više dodatnih rAd26 vektora koji kodiraju HIV antigene polipeptide s aminokiselinskim sljedovima od SEQ ID NO: 1, SEQ ID NO: 3 i SEQ ID NO: 4,
u postupku induciranja imunosnog odgovora protiv virusa humane imunodeficijencije (HIV) kod pojedinca,
gdje navedeni postupak obuhvaća davanje navedenog prvog pripravka za primarnu imunizaciju, davanje navedenog drugog pripravka za dodatnu pojačanu imunizaciju, i davanje imunogenetski učinkovite količine dodatnih rAd26 vektora, pri čemu se navedena imunogenetski učinkovita količina dodatnih rAd26 vektora nalazi u drugom pripravku ili u trećem pripravku koji se daje zajedno s drugim pripravkom za dodatnu pojačanu imunizaciju.
12. Prvi pripravak za uporabu prema patentnom zahtjevu 10 ili drugi pripravak za uporabu prema patentnom zahtjevu 11, naznačeni time, da se imunogenetski učinkovita količina jednog ili više dodatnih rAd26 vektora nalazi u trećem pripravku.
13. Prvi pripravak za uporabu prema patentnom zahtjevu 10 ili 12, ili drugi pripravak za uporabu prema patentnom zahtjevu 11 ili 12, naznačeni time, da se kod pomoćnog sredstva radi o aluminijevom fosfatu ili pomoćnom sredstvu na bazi saponina, pri čemu je poželjno da pomoćno sredstvo bude aluminijev fosfat.
14. Prvi pripravak za uporabu prema patentnom zahtjevu 10 ili 12 ili 13, ili drugi pripravak za uporabu prema patentnom zahtjevu 11 ili 12 ili 13, naznačeni time, da izolirani HIV glikoprotein ovojnice posjeduje aminokiselinski slijed od SEQ ID NO: 5.
15. Prvi pripravak za uporabu prema bilo kojem od patentnih zahtjeva 10 i 12 do 14, ili drugi pripravak za uporabu prema bilo kojem od patentnih zahtjeva 11 i 12 do 14, naznačeni time, da spomenuti imunosni odgovor jest zaštitni imunosni odgovor protiv HIV infekcije.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462056059P | 2014-09-26 | 2014-09-26 | |
| EP15845233.4A EP3197489B1 (en) | 2014-09-26 | 2015-09-24 | Methods and compositions for inducing protective immunity against human immunodeficiency virus infection |
| PCT/US2015/051891 WO2016049287A1 (en) | 2014-09-26 | 2015-09-24 | Methods and compositions for inducing protective immunity against human immunodeficiency virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210608T1 true HRP20210608T1 (hr) | 2021-06-11 |
Family
ID=55581992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210608TT HRP20210608T1 (hr) | 2014-09-26 | 2021-04-16 | Postupci i pripravci za induciranje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US10137191B2 (hr) |
| EP (2) | EP3868398A1 (hr) |
| JP (2) | JP6438575B2 (hr) |
| KR (2) | KR102159626B1 (hr) |
| CN (2) | CN106999571B (hr) |
| AP (1) | AP2017009846A0 (hr) |
| AU (2) | AU2015320574B2 (hr) |
| BR (1) | BR112017005917A2 (hr) |
| CA (1) | CA2961024A1 (hr) |
| CY (1) | CY1124254T1 (hr) |
| DK (1) | DK3197489T3 (hr) |
| EA (2) | EA037583B1 (hr) |
| ES (1) | ES2865150T3 (hr) |
| HR (1) | HRP20210608T1 (hr) |
| HU (1) | HUE053585T2 (hr) |
| IL (2) | IL251114B (hr) |
| LT (1) | LT3197489T (hr) |
| MA (1) | MA40765B1 (hr) |
| MX (2) | MX2017003946A (hr) |
| MY (1) | MY175620A (hr) |
| PH (1) | PH12017500449A1 (hr) |
| PL (1) | PL3197489T3 (hr) |
| PT (1) | PT3197489T (hr) |
| RS (1) | RS61902B1 (hr) |
| SG (1) | SG11201702110RA (hr) |
| SI (1) | SI3197489T1 (hr) |
| WO (1) | WO2016049287A1 (hr) |
| ZA (1) | ZA201702053B (hr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY175620A (en) * | 2014-09-26 | 2020-07-02 | Beth Israel Deaconess Medical Ct Inc | Methods and compositions for inducing protective immunity against human immunodeficiency virus infection |
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| BR112018011122A2 (pt) | 2015-12-15 | 2018-11-21 | Janssen Vaccines & Prevention B.V. | antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos |
| CA3014419A1 (en) | 2016-02-16 | 2017-08-24 | Geovax Inc. | Multivalent hiv vaccine boost compositions and methods of use |
| JP6595132B2 (ja) | 2016-06-16 | 2019-10-23 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Ｈｉｖワクチン製剤 |
| CN110494159A (zh) * | 2016-09-02 | 2019-11-22 | 扬森疫苗与预防公司 | 在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法 |
| HUE052008T2 (hu) | 2016-09-15 | 2021-04-28 | Janssen Vaccines & Prevention Bv | Trimert stabilizáló HIV-burokfehérje-mutációk |
| EA202090049A1 (ru) * | 2017-06-15 | 2020-04-15 | Янссен Вэксинс Энд Превеншн Б.В. | Поксвирусные векторы, кодирующие антигены вич, и способы их применения |
| BR112020000867A2 (pt) | 2017-07-19 | 2020-07-21 | Janssen Vaccines & Prevention B.V. | mutações da proteína do envelope do hiv estabilizando o trímero |
| US20190022212A1 (en) | 2017-07-21 | 2019-01-24 | Beth Israel Deaconess Medical Center, Inc. | Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human |
| WO2019055888A1 (en) * | 2017-09-18 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT |
| US11517618B2 (en) * | 2018-09-25 | 2022-12-06 | Janssen Vaccines & Prevention B.V. | Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components |
| US20220211835A1 (en) * | 2019-04-17 | 2022-07-07 | The Wistar Institute | Replication Deficient Adenoviral Vectors for HIV Vaccine Applications |
| WO2020237052A1 (en) * | 2019-05-22 | 2020-11-26 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| CA3141454A1 (en) * | 2019-05-22 | 2020-11-26 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| JP7454645B2 (ja) | 2019-07-16 | 2024-03-22 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖワクチン並びにその作製方法及び使用方法 |
| AU2020381082B2 (en) * | 2019-11-07 | 2022-09-22 | Janssen Vaccines & Prevention B.V. | Protein purification |
| PE20241071A1 (es) | 2021-01-14 | 2024-05-13 | Gilead Sciences Inc | Vacunas contra el vih y metodos de uso |
| WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
| AU4255397A (en) | 1996-09-06 | 1998-03-26 | Trustees Of The University Of Pennsylvania, The | Chimpanzee adenovirus vectors |
| GB0023203D0 (en) | 2000-09-21 | 2000-11-01 | Isis Innovation | Vaccination method |
| DK1054064T4 (da) | 1999-05-17 | 2010-05-03 | Crucell Holland Bv | Vehikler til adenovirus afledt genafgivelse omfattende mindst et element af adenovirus type 35 |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US6710173B1 (en) | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
| CA2384271A1 (en) | 1999-09-17 | 2001-03-22 | Joseph G. Sodroski | Stabilized soluble glycoprotein trimers |
| CZ295808B6 (cs) | 2000-11-23 | 2005-11-16 | Bavarian Nordic A/S | Modifikovaný virus vakcinie typu Ankara |
| CA2452119C (en) | 2001-07-05 | 2013-10-15 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof |
| CA2466413C (en) | 2001-12-04 | 2014-11-04 | Bavarian Nordic A/S | Flavivirus ns1 subunit vaccine |
| EP1497440B1 (en) | 2002-04-25 | 2008-08-20 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
| KR101021387B1 (ko) | 2002-04-25 | 2011-03-14 | 크루셀 홀란드 비.브이. | 아데노바이러스 벡터를 생산하기 위한 수단 및 방법 |
| AU2003291402A1 (en) | 2002-11-07 | 2004-06-03 | Beth Israel Deaconess Medical Center | MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE |
| CA2505583C (en) | 2002-12-03 | 2014-07-15 | University Of Massachusetts | Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods |
| CA2520637A1 (en) | 2003-03-28 | 2004-10-14 | The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services | Mva virus expressing modified hiv envelope, gag, and pol genes |
| WO2005027840A2 (en) * | 2003-09-15 | 2005-03-31 | Chiron Corporation | Combination approaches for generating immune responses |
| US20070298051A1 (en) | 2003-11-19 | 2007-12-27 | Beth Israel Deaconess Medical Center | Adjuvants Of Immune Response |
| CN107723298A (zh) | 2004-01-23 | 2018-02-23 | Msd意大利有限公司 | 黑猩猩腺病毒疫苗载运体 |
| WO2006002079A2 (en) | 2004-06-15 | 2006-01-05 | Progenics Pharmaceuticals, Inc. | Hiv-1 neutralizing antibodies elicited by trimeric hiv-1 envelope glycoprotein complex |
| JP4772045B2 (ja) | 2004-07-16 | 2011-09-14 | アメリカ合衆国 | Ｃｍｖ／ｒ核酸コンストラクトを含むａｉｄｓに対するワクチン |
| US9453239B2 (en) | 2004-08-27 | 2016-09-27 | Emory University | Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes |
| MX2007004188A (es) | 2004-10-13 | 2007-10-11 | Crucell Holland Bv | Vectores adenovirales mejorados y usos de los mismos. |
| WO2006050394A2 (en) * | 2004-11-01 | 2006-05-11 | Novartis Vaccines And Diagnostics Inc. | Combination approaches for generating immune responses |
| CA2656741A1 (en) | 2005-07-06 | 2007-01-11 | University Of Maryland Biotechnology Institute | Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites |
| WO2007024941A2 (en) | 2005-08-23 | 2007-03-01 | The Regents Of The University Of California | Polyvalent vaccine |
| US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
| US20110076298A1 (en) | 2006-06-19 | 2011-03-31 | Olson William C | Soluble stabilized trimeric hiv env proteins and uses thereof |
| WO2008063331A2 (en) | 2006-10-23 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof |
| US20080279879A1 (en) | 2006-11-17 | 2008-11-13 | New York University | INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE |
| SI2137210T1 (sl) | 2007-03-02 | 2017-01-31 | Glaxosmithkline Biologicals S.A. | Nov postopek in sestavki |
| HUE037270T2 (hu) * | 2008-10-10 | 2018-08-28 | Childrens Medical Center | Biokémiailag stabilizált HIV-1 ENV trimer vakcina |
| NZ602504A (en) | 2008-11-18 | 2014-01-31 | Beth Israel Hospital | Antiviral vaccines with improved cellular immunogenicity |
| WO2010085984A1 (en) | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| SI2391638T1 (sl) | 2009-02-02 | 2018-10-30 | Glaxosmithkline Biologicals Sa | Nukleinskokislinske in aminokislinske sekvence opičjega adenovirusa, vektorji, ki le-te vsebujejo, in njihova uporaba |
| WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
| CN102711794B (zh) | 2010-01-04 | 2015-11-25 | Kj生物科学有限公司 | 用于疫苗和诊断学的Dps融合蛋白 |
| CA2786333C (en) | 2010-01-28 | 2018-03-20 | Bavarian Nordic A/S | Vaccinia virus mutants containing the major genomic deletions of mva |
| CA2786835C (en) * | 2010-02-15 | 2021-08-31 | Crucell Holland B.V. | Method for the production of ad26 adenoviral vectors |
| SI3556396T1 (sl) | 2010-08-31 | 2022-09-30 | Theraclone Sciences, Inc. | Nevtralizacijska protitelesa proti virusu človeške imunske pomanjkljivosti (HIV) |
| AU2011316164B2 (en) | 2010-10-15 | 2016-01-14 | Bavarian Nordic A/S | Recombinant modified vaccinia virus Ankara (MVA) influenza vaccine |
| AU2011343798B2 (en) * | 2010-12-14 | 2016-07-14 | Janssen Vaccines & Prevention B.V. | Adenovirus serotype 26 and serotype 35 filovirus vaccines |
| US20140348791A1 (en) | 2011-09-09 | 2014-11-27 | Beth Israel Deaconess Medical Center, Inc. | Modified adenoviral vectors and methods of treatment using same |
| CA2789539A1 (en) | 2011-09-12 | 2013-03-12 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| EP2766037A4 (en) | 2011-10-12 | 2015-08-05 | Scripps Research Inst | HIV-1 GP-120 MINI-V3 LOOP AND USES THEREOF |
| US9683268B2 (en) | 2012-09-19 | 2017-06-20 | Beth Israel Deaconess | Viruses associated with immunodeficiency and enteropathy and methods using same |
| CN105051198A (zh) | 2012-11-16 | 2015-11-11 | 貝丝以色列女执事医疗中心 | 重组腺病毒及其用途 |
| JP6357487B2 (ja) | 2013-01-07 | 2018-07-11 | ベス イスラエル デアコネス メディカル センター インコーポレイテッド | 安定化ヒト免疫不全ウイルス（ｈｉｖ）エンベロープ（ｅｎｖ）トリマーワクチン及びそれを使用する方法 |
| WO2014124301A1 (en) | 2013-02-07 | 2014-08-14 | University Of Washington Through Its Center For Commercialization | Self-assembling protein nanostructures |
| EP3052132B1 (en) | 2013-09-30 | 2020-07-29 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| CN103992396B (zh) * | 2014-04-17 | 2017-03-29 | 南开大学 | 一种潜在的高效重组HIV‑1 CRF07‑BC gp140免疫原的制备方法 |
| WO2016037154A1 (en) | 2014-09-04 | 2016-03-10 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Recombinant hiv-1 envelope proteins and their use |
| MY175620A (en) | 2014-09-26 | 2020-07-02 | Beth Israel Deaconess Medical Ct Inc | Methods and compositions for inducing protective immunity against human immunodeficiency virus infection |
| US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| BR112018011122A2 (pt) | 2015-12-15 | 2018-11-21 | Janssen Vaccines & Prevention B.V. | antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos |
| CN110494159A (zh) * | 2016-09-02 | 2019-11-22 | 扬森疫苗与预防公司 | 在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法 |
-
2015
- 2015-09-24 MY MYPI2017700998A patent/MY175620A/en unknown
- 2015-09-24 DK DK15845233.4T patent/DK3197489T3/da active
- 2015-09-24 JP JP2017516371A patent/JP6438575B2/ja not_active Expired - Fee Related
- 2015-09-24 EP EP21157436.3A patent/EP3868398A1/en not_active Withdrawn
- 2015-09-24 EA EA201790717A patent/EA037583B1/ru unknown
- 2015-09-24 AP AP2017009846A patent/AP2017009846A0/en unknown
- 2015-09-24 PL PL15845233T patent/PL3197489T3/pl unknown
- 2015-09-24 MA MA40765A patent/MA40765B1/fr unknown
- 2015-09-24 AU AU2015320574A patent/AU2015320574B2/en not_active Ceased
- 2015-09-24 EP EP15845233.4A patent/EP3197489B1/en active Active
- 2015-09-24 BR BR112017005917A patent/BR112017005917A2/pt not_active Application Discontinuation
- 2015-09-24 CN CN201580063229.2A patent/CN106999571B/zh not_active Expired - Fee Related
- 2015-09-24 CA CA2961024A patent/CA2961024A1/en active Pending
- 2015-09-24 MX MX2017003946A patent/MX2017003946A/es unknown
- 2015-09-24 HU HUE15845233A patent/HUE053585T2/hu unknown
- 2015-09-24 WO PCT/US2015/051891 patent/WO2016049287A1/en active Application Filing
- 2015-09-24 SG SG11201702110RA patent/SG11201702110RA/en unknown
- 2015-09-24 KR KR1020197010330A patent/KR102159626B1/ko active IP Right Grant
- 2015-09-24 RS RS20210546A patent/RS61902B1/sr unknown
- 2015-09-24 KR KR1020177011034A patent/KR101971808B1/ko active IP Right Grant
- 2015-09-24 ES ES15845233T patent/ES2865150T3/es active Active
- 2015-09-24 PT PT158452334T patent/PT3197489T/pt unknown
- 2015-09-24 LT LTEP15845233.4T patent/LT3197489T/lt unknown
- 2015-09-24 EA EA202092521A patent/EA202092521A1/ru unknown
- 2015-09-24 CN CN202011101485.5A patent/CN112121160A/zh active Pending
- 2015-09-24 US US14/863,808 patent/US10137191B2/en active Active
- 2015-09-24 SI SI201531597T patent/SI3197489T1/sl unknown
-
2017
- 2017-03-09 PH PH12017500449A patent/PH12017500449A1/en unknown
- 2017-03-13 IL IL251114A patent/IL251114B/en active IP Right Grant
- 2017-03-23 ZA ZA2017/02053A patent/ZA201702053B/en unknown
- 2017-03-24 MX MX2020013153A patent/MX2020013153A/es unknown
-
2018
- 2018-05-02 US US15/968,834 patent/US10471137B2/en active Active
- 2018-11-15 JP JP2018214706A patent/JP6625716B2/ja not_active Expired - Fee Related
- 2018-11-23 AU AU2018267669A patent/AU2018267669B2/en not_active Ceased
-
2019
- 2019-03-31 IL IL265733A patent/IL265733B/en active IP Right Grant
- 2019-10-04 US US16/593,658 patent/US11207400B2/en active Active
-
2021
- 2021-04-16 HR HRP20210608TT patent/HRP20210608T1/hr unknown
- 2021-05-07 CY CY20211100391T patent/CY1124254T1/el unknown
- 2021-12-06 US US17/457,705 patent/US20220096622A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210608T1 (hr) | Postupci i pripravci za induciranje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije | |
| MX2021006931A (es) | Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos. | |
| RU2015132962A (ru) | Иммуногенные композиции на основе вируса гриппа и их применение | |
| UA114086C2 (xx) | Імуногенна композиція глікопротеїну g вірусу hendra і/або nipah | |
| WO2020063370A3 (zh) | 免疫组合物及其制备方法与应用 | |
| HRP20200285T1 (hr) | Postupci i pripravci za induciranje zaštitnog imuniteta protiv zaraze filovirusom | |
| MX2021015465A (es) | Vacuna para fiebre porcina africana. | |
| EA201892735A1 (ru) | Состав вакцины против hiv | |
| MX2023007395A (es) | Vacunas del virus de la peste porcina africana (ppa). | |
| Lowell et al. | Back to the future: Immunization with M-001 prior to trivalent influenza vaccine in 2011/12 enhanced protective immune responses against 2014/15 epidemic strain | |
| BR112015017966A2 (pt) | composições imunogênicas compreendendo vírus silificado e métodos de uso | |
| CO6561819A2 (es) | Vectores para vacunas y método para potenciar respuestas inmunes | |
| BR112014015390A8 (pt) | vírus da estomatite vesicular para vacinas iniciais e de reforço | |
| CL2017003224A1 (es) | Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante | |
| BR112015032556A2 (pt) | Proteína matriz (m) modificada de um vírus da estomatite vesicular (vsv); sequência de nucleotídeos que codifica uma proteína matriz modificada de um vírus da estomatite vesicular; vírus da estomatite vesicular recombinante (rvsv); vacina; vacina de combinação de preparação e reforço; kit; peptídeo isolado; sequências de nucleotídeos isoladas; uso da vacina; uso da vacina de combinação de preparação e reforço; método para induzir uma resposta imunológica em um indivíduo | |
| JP2013545448A5 (hr) | ||
| RU2018123307A (ru) | Вакцинация с использованием альфа3 домена mica/b для лечения рака | |
| WO2018055535A3 (en) | Hepatitis c virus immunogenic compositions and methods of use thereof | |
| PE20170429A1 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
| US20170021009A1 (en) | Heat Inactivated Poxvirus Improves Vaccination Results | |
| AR054259A1 (es) | Vacuna contra virus de papiloma humano (hpv) | |
| AR076437A1 (es) | Composicion inmunologica, equipo para provocar una respuesta inmune y metodo para provocar una respuesta inmune contra befv en un animal | |
| JP2015525794A5 (hr) | ||
| RU2014140168A (ru) | Улучшенная вакцинация против гриппа | |
| NZ583377A (en) | Method of eliciting an immune response against pandemic influenza virus |